NCT06109207 2024-07-23Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell CarcinomasWest China HospitalPhase 1 Recruiting6 enrolled
NCT06225921 2024-03-06Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell CarcinomasWest China HospitalPhase 1 Recruiting6 enrolled